Mundipharma Receives EU Approval for Pelmeg (Pegfilgrastim, Biosimilar)

Shots:

• Pelmeg (Pegfilgrastim, Biosimilar) is indicated to reduce the duration of neutropenia and the incidence of febrile neutropenia in patients treated with cytotoxic CT for malignancy
• CHMP recommends Pelmeg based on the results from pharmacodynamics, pharmacokinetics, and immunogenicity comparisons with Neulasta
• Pelmeg is Granulocyte-colony stimulating factor (G-CSF) biosimilar that stimulates bone marrow to produce more neutrophils riginally developed by Cinfa Biotech

Click here to read full press release/ article | Ref: Mundipharma | Image: Wikimedia Commons